New drug combo tested for Tough-to-Treat head and neck cancers
NCT ID NCT05245682
Summary
This early safety study is testing a new oral drug called tolinapant given alongside standard radiation therapy. It is for patients with locally advanced head and neck cancer who cannot receive the usual chemotherapy drug, cisplatin. The main goal is to see if the combination is safe and tolerable, while also checking if it helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.